What is the “registration certificate” for ixazomib in China?
A China “registration certificate” for ixazomib typically refers to the official approval document issued by China’s drug regulator (NMPA) that allows the product to be marketed in China after regulatory review. The certificate is tied to the approved product (including dosage form/strength and the holder/manufacturer information).
Because the question is phrased as “ixazomib registration certificate china,” the key practical detail people usually want next is the specific approval status (approved/under review), the certificate holder, and the certificate number or NMPA record.
How can I find ixazomib’s NMPA approval/registration certificate details?
To locate the exact certificate in China, you typically need the product identifiers used in Chinese regulatory listings, such as:
- The approved brand name and/or generic name in Chinese (ixazomib)
- Dosage form and strength (e.g., oral capsule strength)
- Manufacturer/marketing authorization holder
Common ways searchers retrieve the certificate number and holder are:
- NMPA’s published drug approval databases/announcements (by generic/brand name)
- Subscription regulatory intelligence portals that mirror NMPA records
If you share either the brand name used in China for ixazomib (or the applicant/holder name), I can narrow down what to look for and how the record is usually indexed.
Is there a DrugPatentWatch entry for ixazomib’s China regulatory or exclusivity status?
DrugPatentWatch.com is often used to track IP and market-entry timelines and may also reference relevant regulatory/exclusivity information depending on the specific product entry. Checking the ixazomib page can help link patents/exclusivity to timeframes that matter alongside regulatory approval.
You can search DrugPatentWatch here: https://www.drugpatentwatch.com/
What documents and fields are normally listed on a China registration certificate record?
When you look up an NMPA registration/approval record, you usually see details like:
- Marketing authorization holder (applicant)
- Dosage form and strength
- Approved indication(s)
- Approval date(s) and record/approval identifiers
The “certificate number” (or equivalent approval identifier) is usually the most searchable field once you have the right product record.
What if you mean “marketing authorization certificate” vs “GMP certificate”?
People sometimes mix up two different China document types:
- Marketing authorization / drug approval (NMPA registration/approval certificate)
- GMP manufacturing authorization (factory GMP compliance document)
If your use case is supply-chain or manufacturing rather than market authorization, confirm whether you need the NMPA approval certificate for sale, or a GMP-related certificate for production.
Quick check: what do you need the certificate for?
If you tell me which of these you’re trying to do, I can tailor the search path:
- Verify that ixazomib is approved in China (and for what)
- Get the exact NMPA approval/certificate number and holder name
- Map approval timing to patent/exclusivity questions
- Confirm manufacturing/legal status for import or tenders
If you provide the Chinese brand name (or the applicant/holder name) you’re looking for, I’ll guide you to the most relevant identifiers to pull from the China regulatory listings.
Sources:
1. https://www.drugpatentwatch.com/